Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AMAG

AMAG Pharmaceuticals (AMAG) Stock Price, News & Analysis

AMAG Pharmaceuticals logo

About AMAG Pharmaceuticals Stock (NASDAQ:AMAG)

Advanced Chart

Key Stats

Today's Range
$13.75
$13.75
50-Day Range
$13.69
$13.75
52-Week Range
$4.41
$13.80
Volume
N/A
Average Volume
950,664 shs
Market Capitalization
$477.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive AMAG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AMAG Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AMAG Stock News Headlines

AMAG Pharmaceuticals, Inc. (AMU.DE)
A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.tc pixel
Alkeus Pharmaceuticals Appoints David Arkowitz as Chief Financial Officer
KalVista Appoints Brian Piekos as Chief Financial Officer
See More Headlines

AMAG Stock Analysis - Frequently Asked Questions

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) posted its quarterly earnings results on Monday, May, 11th. The specialty pharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.27. The specialty pharmaceutical company had revenue of $68.66 million for the quarter, compared to the consensus estimate of $64.95 million. AMAG Pharmaceuticals had a negative trailing twelve-month return on equity of 16.92% and a negative net margin of 74.93%.

Based on aggregate information from My MarketBeat watchlists, some other companies that AMAG Pharmaceuticals investors own include Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Meta Platforms (META), Bausch Health Cos (BHC), Netflix (NFLX) and Tesla (TSLA).

Company Calendar

Last Earnings
5/11/2020
Today
9/13/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AMAG
CIK
792977
Fax
N/A
Employees
440
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($6.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$466.46 million
Net Margins
-74.93%
Pretax Margin
N/A
Return on Equity
-16.92%
Return on Assets
-5.96%

Debt

Debt-to-Equity Ratio
1.13
Current Ratio
1.75
Quick Ratio
1.45

Sales & Book Value

Annual Sales
$327.75 million
Price / Sales
1.46
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.37 per share
Price / Book
1.87

Miscellaneous

Outstanding Shares
34,725,000
Free Float
N/A
Market Cap
$477.47 million
Optionable
Optionable
Beta
0.89
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:AMAG) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners